Merrill Lynch keeps MedImmune at neutral

MedImmune Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating as the company expects to release data in the fourth quarter of this year from a study comparing the company's nasal flu vaccine CAIV-T to injectable flu vaccine. Success would be judged if CAIV-T improves immunity by 20%, allowing for product differentiation, Merrill Lynch said. The company's value could vary widely depending on data from the phase III trial, Merrill Lynch said, and there is a risk that investors could decide to sell off whether the data is positive or not. Shares of the Gaithersburg, Md.-based biotechnology company were down $0.93, or 2.59%, at $34.94 on volume of 2,638,253 shares versus the three-month running average of 2,810,700 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.